Skip to content

A head-to-head randomized controlled study comparing spinal cord electrical stimulation combined with platelet-rich plasma with combined pulsed radiofrequency in the treatment of refractory post-herpetic neuralgia

A head-to-head randomized controlled study comparing spinal cord electrical stimulation combined with platelet-rich plasma with combined pulsed radiofrequency in the treatment of refractory post-herpetic neuralgia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122366
Enrollment
Unknown
Registered
2026-04-13
Start date
2026-04-13
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia

Interventions

SCS + PRP group:Stimulation electrodes were inserted through epidural puncture for short-term SCS stimulation for 7 to 14 days. After testing showed effectiveness, a permanent stimulator was implanted
ultrasound-guided injections into the target nerve/paravertebral area/DRG were performed
the PRP concentration was 3 to 5 times that of whole blood, 1.0 to 2.0 mL per segment
it was administered once every 2 to 4 weeks for a total of 2 times.
SCS + PRF group:Stimulation electrodes were inserted through epidural puncture for short-term SCS stimulation for 7 to 14 days. After testing showed effectiveness, a permanent stimulator was implanted
standard PRF parameters: 42°C, 600s, 2Hz, 20ms
targeted nerve/DRG target point treatment, with only one treatment session.

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 40–85 years; gender is not restricted; 2. Meets the diagnostic criteria for PHN, with a pain duration of >=3 months; 3. NRS pain score of >= 6, with poor response to standard pharmacological treatment; 4. Meets the indications for SCS treatment, is willing to participate in the study and has signed an informed consent form; 5. Is able to cooperate with follow-up visits and assessments.

Exclusion criteria

Exclusion criteria: 1. Coagulation disorders, bleeding tendencies, active infections, or sepsis; 2. Skin infections at the injection site, severe spinal deformities, or spinal stenosis; 3. Malignant tumors, severe cardiovascular or cerebrovascular diseases, and hepatic or renal insufficiency; 4. Pregnant or lactating women; 5. Mental illness, cognitive impairment, or inability to cooperate with the investigator; 6. Patients who have received PRF or PRP treatment within the past month; 7. Other conditions deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
The proportion of patients whose pain relief was >=50% after 6 months of treatment (efficacy rate);;NRS pain scores.;

Countries

China

Contacts

Public ContactQinchao

Tianjin Medical University General Hospital

qinchao0828@126.com+86 155 1096 3226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026